CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Pens
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Syringes
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Others
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Type 1 Diabetes
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Type 2 Diabetes
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Gestational Diabetes
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN
6.1. Market Overview
6.1.1 Market Size and Forecast, By Type Of Insulin
6.2. Rapid-acting Insulin
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Short-acting Insulin
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Intermediate-acting Insulin
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Others
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL
7.1. Market Overview
7.1.1 Market Size and Forecast, By Distribution Channel
7.2. Hospital Pharmacies
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Drug Stores And Retail Pharmacies
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Online Providers
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: HUMAN INSULIN MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Product Type
8.2.3. Market Size and Forecast, By Indication
8.2.4. Market Size and Forecast, By Type Of Insulin
8.2.5. Market Size and Forecast, By Distribution Channel
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Human Insulin Market
8.2.7.1. Market Size and Forecast, By Product Type
8.2.7.2. Market Size and Forecast, By Indication
8.2.7.3. Market Size and Forecast, By Type Of Insulin
8.2.7.4. Market Size and Forecast, By Distribution Channel
8.2.8. Canada Human Insulin Market
8.2.8.1. Market Size and Forecast, By Product Type
8.2.8.2. Market Size and Forecast, By Indication
8.2.8.3. Market Size and Forecast, By Type Of Insulin
8.2.8.4. Market Size and Forecast, By Distribution Channel
8.2.9. Mexico Human Insulin Market
8.2.9.1. Market Size and Forecast, By Product Type
8.2.9.2. Market Size and Forecast, By Indication
8.2.9.3. Market Size and Forecast, By Type Of Insulin
8.2.9.4. Market Size and Forecast, By Distribution Channel
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Product Type
8.3.3. Market Size and Forecast, By Indication
8.3.4. Market Size and Forecast, By Type Of Insulin
8.3.5. Market Size and Forecast, By Distribution Channel
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Human Insulin Market
8.3.7.1. Market Size and Forecast, By Product Type
8.3.7.2. Market Size and Forecast, By Indication
8.3.7.3. Market Size and Forecast, By Type Of Insulin
8.3.7.4. Market Size and Forecast, By Distribution Channel
8.3.8. France Human Insulin Market
8.3.8.1. Market Size and Forecast, By Product Type
8.3.8.2. Market Size and Forecast, By Indication
8.3.8.3. Market Size and Forecast, By Type Of Insulin
8.3.8.4. Market Size and Forecast, By Distribution Channel
8.3.9. UK Human Insulin Market
8.3.9.1. Market Size and Forecast, By Product Type
8.3.9.2. Market Size and Forecast, By Indication
8.3.9.3. Market Size and Forecast, By Type Of Insulin
8.3.9.4. Market Size and Forecast, By Distribution Channel
8.3.10. Italy Human Insulin Market
8.3.10.1. Market Size and Forecast, By Product Type
8.3.10.2. Market Size and Forecast, By Indication
8.3.10.3. Market Size and Forecast, By Type Of Insulin
8.3.10.4. Market Size and Forecast, By Distribution Channel
8.3.11. Spain Human Insulin Market
8.3.11.1. Market Size and Forecast, By Product Type
8.3.11.2. Market Size and Forecast, By Indication
8.3.11.3. Market Size and Forecast, By Type Of Insulin
8.3.11.4. Market Size and Forecast, By Distribution Channel
8.3.12. Rest Of Europe Human Insulin Market
8.3.12.1. Market Size and Forecast, By Product Type
8.3.12.2. Market Size and Forecast, By Indication
8.3.12.3. Market Size and Forecast, By Type Of Insulin
8.3.12.4. Market Size and Forecast, By Distribution Channel
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Product Type
8.4.3. Market Size and Forecast, By Indication
8.4.4. Market Size and Forecast, By Type Of Insulin
8.4.5. Market Size and Forecast, By Distribution Channel
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Human Insulin Market
8.4.7.1. Market Size and Forecast, By Product Type
8.4.7.2. Market Size and Forecast, By Indication
8.4.7.3. Market Size and Forecast, By Type Of Insulin
8.4.7.4. Market Size and Forecast, By Distribution Channel
8.4.8. China Human Insulin Market
8.4.8.1. Market Size and Forecast, By Product Type
8.4.8.2. Market Size and Forecast, By Indication
8.4.8.3. Market Size and Forecast, By Type Of Insulin
8.4.8.4. Market Size and Forecast, By Distribution Channel
8.4.9. India Human Insulin Market
8.4.9.1. Market Size and Forecast, By Product Type
8.4.9.2. Market Size and Forecast, By Indication
8.4.9.3. Market Size and Forecast, By Type Of Insulin
8.4.9.4. Market Size and Forecast, By Distribution Channel
8.4.10. Australia Human Insulin Market
8.4.10.1. Market Size and Forecast, By Product Type
8.4.10.2. Market Size and Forecast, By Indication
8.4.10.3. Market Size and Forecast, By Type Of Insulin
8.4.10.4. Market Size and Forecast, By Distribution Channel
8.4.11. South Korea Human Insulin Market
8.4.11.1. Market Size and Forecast, By Product Type
8.4.11.2. Market Size and Forecast, By Indication
8.4.11.3. Market Size and Forecast, By Type Of Insulin
8.4.11.4. Market Size and Forecast, By Distribution Channel
8.4.12. Rest of Asia-Pacific Human Insulin Market
8.4.12.1. Market Size and Forecast, By Product Type
8.4.12.2. Market Size and Forecast, By Indication
8.4.12.3. Market Size and Forecast, By Type Of Insulin
8.4.12.4. Market Size and Forecast, By Distribution Channel
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Product Type
8.5.3. Market Size and Forecast, By Indication
8.5.4. Market Size and Forecast, By Type Of Insulin
8.5.5. Market Size and Forecast, By Distribution Channel
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Human Insulin Market
8.5.7.1. Market Size and Forecast, By Product Type
8.5.7.2. Market Size and Forecast, By Indication
8.5.7.3. Market Size and Forecast, By Type Of Insulin
8.5.7.4. Market Size and Forecast, By Distribution Channel
8.5.8. Saudi Arabia Human Insulin Market
8.5.8.1. Market Size and Forecast, By Product Type
8.5.8.2. Market Size and Forecast, By Indication
8.5.8.3. Market Size and Forecast, By Type Of Insulin
8.5.8.4. Market Size and Forecast, By Distribution Channel
8.5.9. South Africa Human Insulin Market
8.5.9.1. Market Size and Forecast, By Product Type
8.5.9.2. Market Size and Forecast, By Indication
8.5.9.3. Market Size and Forecast, By Type Of Insulin
8.5.9.4. Market Size and Forecast, By Distribution Channel
8.5.10. Rest of LAMEA Human Insulin Market
8.5.10.1. Market Size and Forecast, By Product Type
8.5.10.2. Market Size and Forecast, By Indication
8.5.10.3. Market Size and Forecast, By Type Of Insulin
8.5.10.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping Of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Eli Lilly And Company
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Sanofi
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Novo Nordisk A/S
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Pfizer
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Biocon
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Wockhardt
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. MannKind Corporation
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Medtronic
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Lupin
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 2. HUMAN INSULIN MARKET FOR PENS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. HUMAN INSULIN MARKET FOR SYRINGES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. HUMAN INSULIN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 6. HUMAN INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. HUMAN INSULIN MARKET FOR TYPE 2 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. HUMAN INSULIN MARKET FOR GESTATIONAL DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. GLOBAL HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 10. HUMAN INSULIN MARKET FOR RAPID-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. HUMAN INSULIN MARKET FOR SHORT-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. HUMAN INSULIN MARKET FOR INTERMEDIATE-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. HUMAN INSULIN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. GLOBAL HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 15. HUMAN INSULIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. HUMAN INSULIN MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. HUMAN INSULIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 18. HUMAN INSULIN MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 20. NORTH AMERICA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 21. NORTH AMERICA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 22. NORTH AMERICA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 23. NORTH AMERICA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 24. U.S. HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 25. U.S. HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 26. U.S. HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 27. U.S. HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 28. CANADA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 29. CANADA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 30. CANADA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 31. CANADA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 32. MEXICO HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 33. MEXICO HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 34. MEXICO HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 35. MEXICO HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 36. EUROPE HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 37. EUROPE HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 38. EUROPE HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 39. EUROPE HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 40. EUROPE HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 41. GERMANY HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 42. GERMANY HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 43. GERMANY HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 44. GERMANY HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 45. FRANCE HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 46. FRANCE HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 47. FRANCE HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 48. FRANCE HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 49. UK HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 50. UK HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 51. UK HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 52. UK HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 53. ITALY HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 54. ITALY HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 55. ITALY HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 56. ITALY HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 57. SPAIN HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 58. SPAIN HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 59. SPAIN HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 60. SPAIN HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 61. REST OF EUROPE HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 62. REST OF EUROPE HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 63. REST OF EUROPE HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 64. REST OF EUROPE HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 65. ASIA-PACIFIC HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 66. ASIA-PACIFIC HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 67. ASIA-PACIFIC HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 68. ASIA-PACIFIC HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 69. ASIA-PACIFIC HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 70. JAPAN HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 71. JAPAN HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 72. JAPAN HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 73. JAPAN HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 74. CHINA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 75. CHINA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 76. CHINA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 77. CHINA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 78. INDIA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 79. INDIA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 80. INDIA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 81. INDIA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 82. AUSTRALIA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 83. AUSTRALIA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 84. AUSTRALIA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 85. AUSTRALIA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 86. SOUTH KOREA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 87. SOUTH KOREA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 88. SOUTH KOREA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 89. SOUTH KOREA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 90. REST OF ASIA-PACIFIC HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 91. REST OF ASIA-PACIFIC HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 92. REST OF ASIA-PACIFIC HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 93. REST OF ASIA-PACIFIC HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 94. LAMEA HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 95. LAMEA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 96. LAMEA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 97. LAMEA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 98. LAMEA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 99. BRAZIL HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 100. BRAZIL HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 101. BRAZIL HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 102. BRAZIL HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 103. SAUDI ARABIA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 104. SAUDI ARABIA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 105. SAUDI ARABIA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 106. SAUDI ARABIA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 107. SOUTH AFRICA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 108. SOUTH AFRICA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 109. SOUTH AFRICA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 110. SOUTH AFRICA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 111. REST OF LAMEA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 112. REST OF LAMEA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 113. REST OF LAMEA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 114. REST OF LAMEA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 115. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 116. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 117. ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 118. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 119. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. SANOFI: KEY EXECUTIVES
TABLE 121. SANOFI: COMPANY SNAPSHOT
TABLE 122. SANOFI: OPERATING SEGMENTS
TABLE 123. SANOFI: PRODUCT PORTFOLIO
TABLE 124. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 126. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 127. NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 128. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 129. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. PFIZER: KEY EXECUTIVES
TABLE 131. PFIZER: COMPANY SNAPSHOT
TABLE 132. PFIZER: OPERATING SEGMENTS
TABLE 133. PFIZER: PRODUCT PORTFOLIO
TABLE 134. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 135. BIOCON: KEY EXECUTIVES
TABLE 136. BIOCON: COMPANY SNAPSHOT
TABLE 137. BIOCON: OPERATING SEGMENTS
TABLE 138. BIOCON: PRODUCT PORTFOLIO
TABLE 139. BIOCON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 140. WOCKHARDT: KEY EXECUTIVES
TABLE 141. WOCKHARDT: COMPANY SNAPSHOT
TABLE 142. WOCKHARDT: OPERATING SEGMENTS
TABLE 143. WOCKHARDT: PRODUCT PORTFOLIO
TABLE 144. WOCKHARDT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 145. MANNKIND CORPORATION: KEY EXECUTIVES
TABLE 146. MANNKIND CORPORATION: COMPANY SNAPSHOT
TABLE 147. MANNKIND CORPORATION: OPERATING SEGMENTS
TABLE 148. MANNKIND CORPORATION: PRODUCT PORTFOLIO
TABLE 149. MANNKIND CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 151. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 152. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
TABLE 153. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 154. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 155. MEDTRONIC: KEY EXECUTIVES
TABLE 156. MEDTRONIC: COMPANY SNAPSHOT
TABLE 157. MEDTRONIC: OPERATING SEGMENTS
TABLE 158. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 159. MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 160. LUPIN: KEY EXECUTIVES
TABLE 161. LUPIN: COMPANY SNAPSHOT
TABLE 162. LUPIN: OPERATING SEGMENTS
TABLE 163. LUPIN: PRODUCT PORTFOLIO
TABLE 164. LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL HUMAN INSULIN MARKET SEGMENTATION
FIGURE 2. GLOBAL HUMAN INSULIN MARKET
FIGURE 3. SEGMENTATION HUMAN INSULIN MARKET
FIGURE 4. TOP INVESTMENT POCKET IN HUMAN INSULIN MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHUMAN INSULIN MARKET
FIGURE 11. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY PRODUCT TYPE
FIGURE 12. HUMAN INSULIN MARKET FOR PENS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. HUMAN INSULIN MARKET FOR SYRINGES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. HUMAN INSULIN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY INDICATION
FIGURE 16. HUMAN INSULIN MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. HUMAN INSULIN MARKET FOR TYPE 2 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. HUMAN INSULIN MARKET FOR GESTATIONAL DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY TYPE OF INSULIN
FIGURE 20. HUMAN INSULIN MARKET FOR RAPID-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. HUMAN INSULIN MARKET FOR SHORT-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. HUMAN INSULIN MARKET FOR INTERMEDIATE-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. HUMAN INSULIN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
FIGURE 25. HUMAN INSULIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. HUMAN INSULIN MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 27. HUMAN INSULIN MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 28. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 29. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 30. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 31. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 32. COMPETITIVE DASHBOARD
FIGURE 33. COMPETITIVE HEATMAP: HUMAN INSULIN MARKET
FIGURE 34. TOP PLAYER POSITIONING, 2023
FIGURE 35. ELI LILLY AND COMPANY: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. NOVO NORDISK A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. PFIZER: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. BIOCON: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. BIOCON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. BIOCON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. WOCKHARDT: NET SALES, 2021-2023 ($BILLION)
FIGURE 51. WOCKHARDT: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. WOCKHARDT: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. MANNKIND CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 54. MANNKIND CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. MANNKIND CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 56. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 57. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 58. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 59. MEDTRONIC: NET SALES, 2021-2023 ($BILLION)
FIGURE 60. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 61. MEDTRONIC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 62. LUPIN: NET SALES, 2021-2023 ($BILLION)
FIGURE 63. LUPIN: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 64. LUPIN: REVENUE SHARE, BY REGION, 2023 (%)
